在瘤微环境中对矩阵金属蛋白酶表达的低氧效应和治疗前景
Georgina Gonzalez-Avila1, Bettina Sommer2, Edgar Flores-Soto3
1Laboratorio de Oncología Biomédica, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
International journal of molecular sciences
|December 9, 2023
概括
瘤微环境中的缺氧 (TME) 通过缺氧诱导因子 (HIF) 促进癌症的进展和免疫逃避. 本综述探讨了HIF和其他途径如何调节低氧TME中的矩阵金属蛋白酶 (MMP),并讨论了针对MMP的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 瘤微环境 (TME) 通常以缺氧 (低氧) 和酸性为特征.
- 缺氧通过缺氧诱导因子 (HIF) 影响癌症进展,促进免疫逃避,DNA修复,代谢变化和转移.
- 癌细胞在对TME的反应中升级矩阵金属蛋白酶 (MMPs),促进瘤细胞的迁移.
研究的目的:
- 在正常和缺氧TME条件下审查MMPs的监管.
- 检查HIF和HIF独立途径在MMP转录中的作用.
- 讨论针对MMP在癌症治疗中的治疗策略.
主要方法:
- 对TME,缺氧,HIF和MMP研究的文献综述.
- 在低氧压力下分析MMP的转录调节机制.
- 检查针对MMP的当前和潜在治疗方法.
主要成果:
- 缺氧显著影响癌细胞的行为,并通过HIF激活促进转移.
- MMPs对于癌细胞迁移至关重要,它们的表达受到HIF依赖和独立途径的影响.
- 并非所有MMP都受到HIF结合低氧反应元素 (HREs) 的直接调节.
结论:
- 了解低氧TME中MMPs的复杂调节对于开发有效的癌症疗法至关重要.
- 单独或与其他治疗相结合地向MMP,有望克服低氧TME引起的治疗耐药性.
- 对控制MMP的HIF依赖和独立途径的进一步研究可以揭示新的治疗点.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Role of Matrix Metalloproteases in Degradation of ECM
2.4K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


